Photocure

PHO · Oslo Børs · Healthcare

49.00NOK +0.6%last day

Price as of 2 October 2026

The price over the past year, with dividends: −16.8%

Performance

1 month

−9.1%

1 year

−16.8%

3 years, per year

−4.4%

5 years, per year

−13.6%

Largest fall, 3 years

−67.6%

Below the peak now

−67.5%

Volatility, 1 year

42.5%

Return with dividends reinvested.

Key figures

P/E

17.0

P/B

2.2

Dividend yield

0.0%

Return on equity

+13.0%

Net margin

+11.6%

Market value

135 m USD

Quality, value and trend

Where Photocure stands against every Nordic stock today. 100 is best.

Quality60

Profitability and a sound balance sheet over time. Better than 60% of Nordic stocks.

Value54

The price measured against earnings, assets and cash flow. Better than 54% of Nordic stocks.

Trend19

The price development over the past year. Better than 19% of Nordic stocks.

Combined37

Quality, value and trend together. Better than 37% of Nordic stocks.

About Photocure

Photocure is a company in healthcare, listed on Oslo Børs. The share trades in NOK. It has around 99 employees.

Photocure ASA, together with its subsidiaries, engages in the research, development, production, distribution, marketing, and sale of pharmaceutical products. It operates through two segments, Commercial Franchise and Development Portfolio. The company offers Hexvix/Cysview for the detection and management of bladder cancer. It is also developing Cevira, a photodynamic drug-device combination product candidate for the non-surgical treatment of high-grade cervical dysplasia.

See the full analysis in InvestWiser.

The accounts, dividends, 40 years of charts and the comparison with other stocks are in the app.

See the full analysis